SIGA Technologies

SIGA "designs and develops novel countermeasures to prevent and treat serious infectious diseases, with an emphasis on biological warfare defense. SIGA’s leading program is ST-246®, an oral therapeutic agent active against orthopoxviruses including smallpox. Additional programs target arenaviruses such as Lassa fever, filoviruses such as Ebola and Marburg, flaviviruses such as Dengue fever, and other category A diseases."

Board

Accessed May 2010:

• Eric A. Rose, M.D., Chief Executive Officer and Chairman of the Board
• Ayelet Dugary, Chief Financial Officer
• Dennis E. Hruby, Ph.D., Chief Scientific Officer
• James J. Antal
• Michael J. Bayer
• Thomas E. Constance
• Steven L. Fasman
• Scott M. Hammer
• Joseph W. "Chip" Marshall, III
• Paul G. Savas
• Bruce Slovin
• Michael Weiner

Contact

URL: http://www.siga.com

Resources and articles

Related Sourcewatch

• Jeff Kindler